The outcomes of the GO-VIBRANT trial published in Clinical Rheumatology confirmed that golimumab when used intravenously (IV) resulted in timely and sustained improvements in health-related quality of life (HRQoL) and efficiency from Week 8 through 12 months in PsA patients. This study by Alexis Ogdie et al. also found HRQoL and productivity improvements could be linked with improvements in disease activity and functional capability of the patient.

In this study, a total of 241 patients were given golimumab IV 2 mg per kg at Weeks 0, 4, then each 8 weeks through Week 52 in the Golinumab group. Whereas, placebo at Weeks 0, 4, then each 8 weeks, with crossover golimumab IV 2 mg per kg at Weeks 24, 28, then each 8 weeks throughout Week 52. Different parameters were used to assess HRQoL.

At week 8, greater variations in golimumab group was observed concerning different HRQoL paramters as compared to the placebo group, as shown in below table:

At week 52, similar change from the starting was observed in both the groups. HRQoL and productivity were usually linked with disease activity and functional capability, with sustained relationship from Week 8 till Week 52.